Table 1.
Baseline clinicopathologic and prognostic characteristics of 184 patients with metastatic renal cell carcinoma (mRCC)
| Variable | Total [cases (%)] | Sorafenib group [cases (%)] | Sunitinib group [cases (%)] | P value |
|---|---|---|---|---|
| Total | 184 | 110 | 74 | |
| Sex | 0.336 | |||
| Man | 141 (76.6) | 87 (84.3) | 54 (73.0) | |
| Woman | 43 (23.4) | 23 (25.7) | 20 (27.0) | |
| Age (years) | 0.152 | |||
| <65 | 139 (75.5) | 79 (71.8) | 60 (81.1) | |
| ≥65 | 45 (24.5) | 31 (28.2) | 14 (18.9) | |
| Histology | 0.872 | |||
| Clear cell | 176 (95.7) | 105 (95.5) | 71 (96.0) | |
| Others | 8 (4.3) | 5 (4.5) | 3 (4.0) | |
| Prior nephrectomy | 0.516 | |||
| Yes | 150 (81.5) | 88 (80.0) | 62 (83.8) | |
| No | 34 (18.5) | 22 (20.0) | 12 (16.2) | |
| Prior cytokine therapy | 0.118 | |||
| Yes | 60 (32.6) | 31 (28.2) | 29 (39.2) | |
| No | 124 (67.4) | 79 (71.8) | 45 (60.8) | |
| Fuhrman grade | 0.636 | |||
| 1–2 | 106 (57.6) | 64 (58.2) | 42 (56.8) | |
| 3–4 | 64 (34.8) | 35 (31.8) | 29 (39.2) | |
| Unknown | 14 (7.6) | 11 (10.0) | 3 (4.0) | |
| Number of metastatic sites | 0.084 | |||
| 1 | 134 (72.8) | 75 (68.2) | 59 (79.7) | |
| ≥2 | 50 (27.2) | 35 (31.8) | 15 (20.3) | |
| Metastatic sites | ||||
| Lung | 139 (75.5) | 81 (73.6) | 58 (78.4) | 0.463 |
| Lymph nodes | 44 (23.9) | 29 (26.4) | 15 (20.3) | 0.342 |
| Bone | 19 (10.3) | 12 (10.9) | 7 (9.5) | 0.751 |
| Liver | 15 (8.2) | 12 (10.9) | 3 (4.1) | 0.096 |
| Others | 13 (7.1) | 7 (6.4) | 6 (8.1) | 0.651 |
| MSKCC grade | 0.598 | |||
| Favorable | 86 (46.7) | 49 (44.6) | 37 (50.0) | |
| Intermediate | 73 (39.7) | 46 (41.8) | 27 (36.5) | |
| Poor | 25 (13.6) | 15 (13.6) | 10 (13.5) | |
| IMDC risk | 0.199 | |||
| Good | 100 (54.3) | 57 (51.8) | 43 (58.1) | |
| Intermediate | 73 (39.7) | 44 (40.0) | 29 (39.2) | |
| Poor | 11 (6.0) | 9 (8.2) | 2 (2.7) | |
MSKCC Memorial Sloan-Kettering Cancer Center, IMDC International Metastatic Renal Cell Carcinoma Database Consortium